Rapid Dose Therapeutics Corp. RDTCF
OTC PK
| 05/31/2026 | 02/28/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -11.48% | 2.12% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.48% | 2.12% | |||
| Cost of Revenue | -27.34% | 9.81% | |||
| Gross Profit | 9.40% | -6.49% | |||
| SG&A Expenses | -28.92% | -29.98% | |||
| Depreciation & Amortization | 2.10% | -5.40% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -25.91% | -17.20% | |||
| Operating Income | 47.75% | 35.65% | |||
| Income Before Tax | 28.03% | 37.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 28.03% | 37.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 28.03% | 37.64% | |||
| EBIT | 47.75% | 35.65% | |||
| EBITDA | 50.93% | 39.13% | |||
| EPS Basic | 27.03% | 40.32% | |||
| Normalized Basic EPS | 26.09% | 41.03% | |||
| EPS Diluted | 27.03% | 40.32% | |||
| Normalized Diluted EPS | 26.09% | 41.03% | |||
| Average Basic Shares Outstanding | -0.32% | 3.88% | |||
| Average Diluted Shares Outstanding | -0.32% | 3.88% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||